In cross-sectional studies, elevated blood pressure (BP) is associated with increased left ventricular mass (LVM), which leads to increased cardiovascular morbidity and mortality. Current practice involves a 'watch and wait' approach in younger individuals with borderline-high BP. We investigated if this was a correct assumption. Methods: 1653 participants in the 1946 birth cohort underwent echocardiography at age 60-64 years and LVM indexed to body-surface-area (LVMI) was measured. The relationship between repeated measures of SBP and antihypertensive treatment (HTT-measured at 4 time points: 60-64 (current), 53, 43 and 36 years) and LVMI at 60-64 years was examined using adjusted multiple regression models. Then, multilevel models of SBP were used to estimate person-specific intercepts (SBP at 36 years) and slopes (rate of change in SBP between 36-60/64 years). The intercepts and slopes were included in sex-adjusted linear regression models with LVMI as the outcome. Results: Individuals on HTT, from 43 years onwards, had higher mean LVMI than those who were not on treatment, irrespective of level of BP at the same age ( Table 1 ). The effect of mid-life rate of change in BP (36-53 years) on LVMI at age 60-64 years was 10 times greater than the effect of more recent rate of change (53 years-current). Conclusions: HTT does not normalize LVMI in older individuals. This may be due to irreversible cardiac damage occurring in mid-life in poorly-controlled hypertensives. Early identification and treatment of individuals with rapidly-increasing BP in mid-life may be key to preventing such damage. A review of current guidelines on monitoring and screening of BP may be required. (2012) Background: Zona glomerulosa (ZG)-like aldosteroneproducing adenomas (APAs) are considered rare. However, ZG-like APAs are often smaller than zona fasciculata (ZF)-like, and more readily overlooked or ignored.
Background:
In cross-sectional studies, elevated blood pressure (BP) is associated with increased left ventricular mass (LVM), which leads to increased cardiovascular morbidity and mortality. Current practice involves a 'watch and wait' approach in younger individuals with borderline-high BP. We investigated if this was a correct assumption. Methods: 1653 participants in the 1946 birth cohort underwent echocardiography at age 60-64 years and LVM indexed to body-surface-area (LVMI) was measured. The relationship between repeated measures of SBP and antihypertensive treatment (HTT-measured at 4 time points: 60-64 (current), 53, 43 and 36 years) and LVMI at 60-64 years was examined using adjusted multiple regression models. Then, multilevel models of SBP were used to estimate person-specific intercepts (SBP at 36 years) and slopes (rate of change in SBP between 36-60/64 years). The intercepts and slopes were included in sex-adjusted linear regression models with LVMI as the outcome. Results: Individuals on HTT, from 43 years onwards, had higher mean LVMI than those who were not on treatment, irrespective of level of BP at the same age (Table 1 ). The effect of mid-life rate of change in BP (36-53 years) on LVMI at age 60-64 years was 10 times greater than the effect of more recent rate of change (53 years-current). Conclusions: HTT does not normalize LVMI in older individuals. This may be due to irreversible cardiac damage occurring in mid-life in poorly-controlled hypertensives. Early identification and treatment of individuals with rapidly-increasing BP in mid-life may be key to preventing such damage. A review of current guidelines on monitoring and screening of BP may be required.
2.2. Zona glomerulosa-like aldosterone-producing adenomas of the adrenal are common and distinguishable biochemically from classical zona fasciculata-like Conn's tumours Background: Zona glomerulosa (ZG)-like aldosteroneproducing adenomas (APAs) are considered rare. However, ZG-like APAs are often smaller than zona fasciculata (ZF)-like, and more readily overlooked or ignored.
1 Since ZG-like cells in APAs are atypical, our aim was to show biochemically whether ZG-like APAs are common and distinguishable from ZF-like APAs. Methods: H&E sections from 41 unselected APAs were graded morphologically as ZG-like if X50% 'compact cells', or ZF-like if o50%. Gene expression of 11b-hydroxylase (CYP11B1), 17a-hydroxylase (CYP17A1) (hallmark ZF-genes) and aldosterone synthase (CYP11B2) (ZG-gene) was measured by qPCR in ZG-like (n ¼ 13) and ZF-like APAs (n ¼ 28). Categorical differentiation of two profiles was sought in APAs appearing 'pure' ZF-or ZG-like on morphology. CYP11B1 and CYP11B2 mRNA were visualised using a common primer-pair for RT-PCR, and selective BglI digestion of CYP11B2. Specificity of customised antisera against CYP11B1 and CYP11B2 was demonstrated by respective staining of ZF and ZG in normal adrenal, and enabled their quantification by Western Blot. Results: CYP17A1 expression was 3.9-fold higher in ZF-like APAs than ZG-like APAs (P ¼ 0.02). In 19 of 21 ZF-like APAs, BglI digestion showed higher CYP11B1 than CYP11B2 mRNA expression, whereas five of seven ZG-like APAs had higher CYP11B2 than CYP11B1 (Figure) . Western blot confirmed presence of CYP11B1 protein in all APAs, in a rank order of ZG-APAs { ZF-APAs o peritumoral tissue. For CYP11B2, the rank order was reversed. Conclusion: ZG-like and ZF-like APAs are biochemically distinguishable. Compactness of ZG-cells may reduce APA size and likelihood of early diagnosis. (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) had clinic BP (average of 3) taken by nurses, and ABPM using validated machines. Results: Median age (2381 patients, 53% F) was 56 (42-68) years, 69% were Caucasian and 83% were on antihypertensive treatment (mean drugs: 2.15 ± 1.1). 23% patients had clinic SBP (mm Hg) o140 (mean 128/83±9/18), 33% 140-160 (150/ 90±6/12), 24% 160-180 (169/94±5/19) and 20% 4180 (197/101 ± 14/30) . Mean daytime BP on ABPM was significantly lower in all groups: 127/ 79±11/10, 137/83±12/11, 145/86±14/30 and 157/86 ± 17/14 mm Hg respectively. A positive correlation was found between clinic SBP and the extent of WC effect on ABPM (r ¼ 0.73, P ¼ 0.01). Caucasian ethnicity, female gender and reduced eGFR were independently associated with WC effect (r 2 ¼ 0.534, Po0.001). Conclusion: Our results confirm the observations of Head et al. in a British population and show a strong positive correlation between clinic SBP and WC effect but suggest gender, ethnicity and renal function are also important determinants. The results support current NICE recommendations but suggest that those with Grade 3 hypertension should also have ABPM. We believe these results are applicable to other populations in the UK and elsewhere.
1. Head GA et al. BMJ 2010; 340: 1104 -1111 2.5. Cutting out the white coat: can we predict out of office blood pressure levels using multiple clinic measurements? Sheppard Introduction: Blood pressure (BP) measured repeatedly, often, but not always, decreases. We tested the hypothesis that such changes in clinic BP predict differences between clinic and home BP.
Methods: This was a post-hoc analysis of data from the TASMINH2 trial. All patients were hypertensive, on treatment and had both clinic (6 measurements) and home measurements (over 1 week). Polynomial regression modelling was used to quantify the shape of the change in clinic systolic BP (slope coefficient) measured repeatedly. Mean home systolic BP was subtracted from initial clinic systolic BP. The relationship between the slope coefficient and the home-clinic difference was assessed using Pearson's Correlation. Binary logistic regression and ROC curves were used to estimate the predictive abilities of the slope coefficient for white coat and masked effects.
Results: 220 patients were included in this analysis. The slope coefficient was significantly correlated to home-clinic difference (Pearson correlation 0.512 [Po0.001]). The slope coefficient was predictive of a white coat effect with a sensitivity of 84% and specificity of 54% and a masked effect with a sensitivity of 71% and specificity of 66%. Conclusions: These preliminary data suggest that systolic BP characteristics in the clinic reflect those differences which occur between home and clinic measurements in hypertensive patients on treatment. More research is needed to establish whether these characteristics are sufficiently predictive in a typical primary care population to be used by general practitioners when considering treatment intensification or referring patients for out of clinic monitoring. Conclusions: 1. These data indicate that patients should attempt a trial of salt restriction before expensive therapy with RD. 2. RD has been shown to reduce renin secretion which may render patients more salt sensitive and thus it will be of interest to observe the effects of salt restriction in patients who fail to respond to RD in future studies.
3A.2. Genome-wide association analysis identifies the MTHFR-CLCN6-NPPA-NPPB gene cluster as an important influence on BNP levels-implications for the use of BNP levels in the diagnosis and therapeutic monitoring of heart failure-an ASCOT sub study Brain Natriuretic Peptide (BNP) levels provide insight into Left Ventricular (LV) filling pressures, and are increasingly used in the diagnosis and management of heart failure. We sought to determine if genetic variation influences the relationship between LV filling pressures and BNP levels. 318 000 SNPs were genotyped, and using HapMap 1 972 462 SNPs were imputed, in 737 Caucasian hypertensive ASCOT participants. Serum BNP levels were measured by immunoassay. LV filling pressures were estimated using the ratio of early diastolic transmitral flow velocity to early mitral annular velocity (E/e') measured by echocardiography. Linear regression analysis was performed, assuming an additive genetic model, and adjusting for all major cardiovascular risk factors. 17 SNPs spanning 150 kb of MTHFR-CLCN6-NPPA-NPPB (MCNN) gene cluster on chromosome 1 were associated with BNP (Po10-6). The top-hit SNP was rs6541003, a MTFHR gene SNP. The Table   illustrates that while E/e' did not vary with rs6541003 genotypes, G-allele carriers had higher BNP levels and were more likely to have levels currently regarded as diagnostic of heart failure (4100 pg/ml). This is the first study to demonstrate that genetic variants in the MCNN gene cluster influence BNP levels independently of LV filling pressures. Combining MCNN genotyping with BNP measurement may provide improved sensitivity and specificity to the algorithms that use BNP levels in the diagnosis and management of heart failure. 
Median E/e' [IQR] 7.4[6.3, 8.7] 7.5[6.5, 8.7] 7.3[6.3, 9 .1] 0.87 Median BNP [IQR] 25 [14, 43] 32 [18, 54] 36 [20, 67] 4.9X10 -9
BNP >100 pg/ml (n, %) Methods: A perivascular collar was fitted around the carotid artery of C57BL/6 and TLR7 deficient (TLR7À/À) mice to induce lesion formation. Mice were then treated with saline, the synthetic TLR7 ligand R848, or left untreated. Quantification of intima/media ratio was performed to assess neointima formation following injury. Damage to the elastic laminae in the media was also quantified. Quantitative real-time polymerase chain reaction was used to determine the effect of TLR7 signalling on gene expression of the proatherogenic chemokines CCL5 and CCL2; and the antiatherogenic cytokines IL-10 and TGF-b, in vascular and lymphoid organs. Results: TLR7À/À mice displayed a trend towards increased neointima formation compared to C57BL/ 6 mice. TLR7À/À mice also exhibited more frequent and larger interruptions in the elastic laminae of the injured carotids than C57BL/6 mice, suggesting the presence of medial damage in the absence of TLR7. Chronic TLR7 activation induced significant upregulation of CCL5 and IL10 expression in the spleen and aorta of C57BL/6 mice. Conclusion: TLR7 plays a potentially protective role in maintaining vessel wall integrity in arterial injury. 14 regions were identified which showed association with TIH at Po10 À5 of which 2 were at Po10 À6 . The majority of associated SNPs mapped to genes with unknown relation to water or electrolyte handling, including those coding for cell-cell adhesion molecules. Others were in coding regions of genes with more obvious potential mechanistic plausibility, including an organic acid transporter reported to modulate distal nephron prostaglandins and a TRP channel. Candidate gene regions were also assessed with SNPs reaching significance at Po10
3A
À3 . This small study indicates that genetic predisposition to TIH is likely to be polygenic. Aberrant regulation of renal prostaglandin pathways, ion flux via TRP channels as well as novel electrolyte regulating gene products may be implicated. Further, larger studies are required.
3A.6. Is subclinical hypothyroidism associated with cognitive decline in the elderly? A systematic review Akintola AA, Jansen WM, van Bodegom D, Westendorp RGJ, van der Grond J and van Heemst D Leiden university, Leiden, Netherlands Introduction: Subclinical hypothyroidism (SCH) and cognitive dysfunction are both common in elderly but data on their association are conflicting. The possibility that SCH might be a causal factor in cognitive dysfunction is important because treatment of thyroid dysfunction is relatively straightforward. This systematic review was performed to determine whether SCH is associated with impaired cognition in elderly. Methods: Databases were searched from January 1966 to February 2011, as well as bibliographies of key articles to identify studies that provided risk estimates for cognitive impairment associated with SCH. Studies included are those that assessed the cognitive status of relatively healthy elderly (X65 years) subjects with SCH. SCH was defined as elevated TSH and normal T4. These studies were reviewed for eligibility, assessed for methodological quality, and the data extracted.
Results: Of the 506 potential reports, eight studies (five cross-sectional studies and three prospective cohort studies, in total 9.994 subjects) met the eligibility criteria. Several cognitive domains were tested using different tests, and varying TSH cut-offs were used. A small study (97 subjects) showed statistically significant positive association, two studies found a weak association, and the rest showed no association. Conclusion: This systematic review indicates that subclinical hypothyroidism is not associated with cognitive impairment in the elderly, casting doubt on whether treatment of SCH will reduce cognitive decline. Thus, clinical trials are needed to assess whether thyroxin replacement reduces cognitive decline in subjects with subclinical hypothyroidism. 10.7 9.2 Change -1.5 (-3.9, 0.9); p=0.29 Table 1 Abstracts manage hypertension. Given the large and increasing number of clinic patients, a nurse led intervention was designed to assist patients in the management of their hypertension. Method: Patients participated in a one-to-one nurse led intervention during which they were counselled on compliance, dietary modification, exercise, understanding hypertension and the dangers of poor blood pressure control. Patients received an information sheet covering the advice provided during counselling.
3B.2. MyAction
Results: Thirty seven patients (11 male, mean age 54.5 years, mean number of BP medications 2.4) attended a mean of 3.5 counselling sessions (31 attended follow up sessions for ischemic heart disease and 1.81 for stroke after 11 and 10 years. Aim: One year after publication of 'Management of Hypertension in Pregnancy' (NICE 2010) we investigated the awareness of, and rate of adherence to the follow-up care guidance. Methodology: Follow-up practices were evaluated in primary and secondary care in the East of England, for women post HIP. Knowledge, attitudes and awareness with respect to increased CV risk was also explored. Three specific questionnaires were mailed to 959 GP practices, 20 hospital maternity services, and 418 women post HIP.
Findings: Response rates were 30%, 40% and 32% respectively. Most health-care professionals in primary and secondary care (77% and 68%) were aware of the increased risk of CVD following HIP. Only a minority informed patients of this risk (36% and 10%). Both communication at the primary/secondary care interface and adherence to guidance was poor. 82% of women were unaware of the increased risk, expressing a wish to be informed, enabled, and provided with the opportunity for further monitoring. 68% of women identified their child/children as a key motivating factor with respect to their health. Conclusion: Follow-up care for women post HIP is sub-optimal. Women are poorly informed and unsupported to make informed decisions, specifically at a time when motivation for lifestyle modification may be optimal.
3B.5. Can renin measurement be extended to primary care to inform the stratified medicines approach to hypertension therapy? Objective: Current guidelines mandate use of antihypertensives stratified by patient age/ethnicity predicated on renin levels. Whilst the cost of plasma renin activity (PRA) assay has declined, it is rarely measured in primary care. Manufacturers of PRA assay kits recommend that venous blood samples be placed on ice immediately after phlebotomy for processing within 1 h. We aimed to determine whether routine storage of blood samples would affect the validity of the assay, simulating conditions encountered in primary care.
Design and method:
We investigated PRA levels (Diasorin PRA radioimmunoassay kit) in 20 hypertensives under 3 different storage conditions: K Recommended hospital practice (immediately taken to lab on ice).
K
Transported to the laboratory immediately without ice.
Left at room temperature taken to the laboratory up to several hours later. Results: PRA on samples delivered immediately on ice was statistically lower than both comparators, but there was no difference between the comparators (Wilcoxon-Sign test).
The two comparators at room temperature maintained a highly significant correlation with samples taken according to recommended practice.
There is no correlation between time spent at room temperature (range 1.0-5.25 h) and differences in PRA. Conclusions: There is no clinically important difference in PRA levels under different conditions of sample storage. The results suggest that it is not necessary to store PRA samples on ice which potentially extends utility of the assay into primary care.
4A.1. Proportion of patients with previously uncontrolled hypertension who achieve target blood pressure through participation in the BHS's prevention and treatment of hypertension with algorithm based therapy (PATHWAY) trials Background: Ethical approval requires patients to be informed that their decision whether to participate does not influence clinical care. We have tested the plausibility of this statement by investigating how many previously uncontrolled patients reach target BP, or are diagnosed with secondary hypertension, as a consequence of participating in PATHWAY. Methods: PATHWAY-1 (P1) tests whether BP after 1 year of losartan þ HCTZ is lower in 300 patients treated with combination de novo than in 300 who received monotherapy for the first four months. PATHWAY-2 (P2) is a year-long placebo-controlled crossover among the three NICE-recommended options in 360 pts with resistant hypertension. PATHWAY-3 (P3) compares oral glucose tolerance in 470 patients receiving 6 months high-dose HCTZ, amiloride or half-dose combination in addition to previous treatment. Plasma renin is measured at baseline in all subjects. Results: Per protocol (PP) results are given for the number (%) of subjects completing each trial with SBP o140 mm Hg. For P1 and P3, results are given also for subjects reaching SBP and DBP (o90 mm Hg) targets, and for the intention-to-treat (ITT) population of all randomised subjects who complete or withdraw. Of 180 renins measured to date, 19 and 8, respectively, are o6 or o2 mU/l (normal 6-74)-despite treatment with drugs which normally elevate renin. Of seven patients studied so far, five have an adrenal adenoma. Conclusion: Participation in PATHWAY achieved target BP in almost 3/4 patients with previously uncontrolled hypertension, and is likely to detect the 5% of patients predicted to have adrenal adenomas causing primary aldosteronism. Introduction: Reduced microvascular density or rarefaction, is a consistent finding in essential hypertension (EH). Functional and structural capillary rarefaction occurs in individuals with both sustained and borderline EH, and in their normotensive offspring. Women who develop preeclampsia are at increased risk of hypertension and stroke in later life. We hypothesised that capillary rarefaction precedes the onset of preeclampsia and could play a role in its pathogenesis. Methods: We recruited 322 consecutive Caucasian women in this longitudinal cohort study, of which 305 subjects completed the study. We used intravital video-microscopy to measure basal (i.e. functional) and maximal (i.e. structural) skin capillary densities according to a well-validated protocol. Subjects were studied at 5 consecutive predetermined visits.
Results: Preeclampsia occurred in 16 women (mean onset at 35.6 ± 4.8 weeks) and 272 women had normal pregnancy. In women with normal pregnancy significant reduction in maximal capillary density occurred at 27-32 weeks but had resolved by the puerperium (mean change-4.4 capillaries/ field, 95%CI À8.3 to À0.5). In contrast, in women who later developed preeclampsia, structural rarefaction was greater and occurred earlier at 20-24 weeks (mean change: À7.0 capillaries/field, 95%CI À12.6 to À1.4), and persisted into the puerperium. We also found that the change in soluble Endoglin from 11-16 weeks to 27-32 weeks was significantly correlated with the change in capillary density.
Conclusions: This is the first study to show that significant structural capillary rarefaction precedes the onset of preeclampsia. Capillary rarefaction could play a role in the pathogenesis of this disease. Acknowledgment: The BHF funded this study.
4A.3. Background: Urate is a final breakdown product of purine metabolism and elevated serum levels can cause gout and have been associated with blood pressure levels, metabolic syndrome and cardiovascular (CV) outcomes. Previous genomewide association studies (GWAS) have identified 11 loci influencing urate but explain only 6% of the total serum urate variance implying that further loci remain to be identified. Methods: To investigate genetic variants influencing urate and their relationship to gout and CV disease we undertook a meta-analysis of GWAS (2.5 million variants) and serum urate in 110 000 people of European ancestry. We validated promising signals in 32 000 independent people and tested association with gout in 70 000 individuals. We investigated the impact of gender, conducted pathway analyses, evaluated whether loci were associated in other ancestries and their impact on blood pressure, glucose, diabetes, stroke and coronary artery disease. Results: We validated 27 genome-wide significant SNPs associated with serum urate including 17 novel loci (Po5 Â 10 À8 ). Seventeen of these variants were associated with gout and gender-specific influences on urate were detected for SLC2A9 and ABCG2. Effects were similar amongst individuals of Indian, African American and Japanese ancestry. One urate locus shows overlap with a blood pressure locus but there a genetic risk score of all variants shows no impact on blood pressure, metabolic phenotypes or CV outcomes. Conclusion: This study identifies 17 novel loci for urate and gout. They do not explain epidemiological associations between urate and CV or metabolic phenotypes. Loci will be revealed pending manuscript acceptance. The kidney has long been invoked in the etiology of essential hypertension. This could involve alterations in expression of specific genes and microRNAs (miRNAs). The aim of the present study was to identify at the transcriptome-wide level mRNAs and miRNAs that were differentially expressed between kidneys of 15 untreated hypertensive and 7 normotensive white male subjects of white European ancestry. By microarray technology we found 14 genes and 11 miRNAs that were differentially expressed in the medulla. We then selected and confirmed by real-time quantitative PCR (qPCR) expression differences for NR4A1, NR4A2, NR4A3, PER1 and SIK1mRNAs, and for the miRNAs hsa-miR-638 and hsa-let-7c. Luciferase reporter gene experiments in HEK293 kidney cells confirmed the predicted binding of hsa-let-7c to the 3 0 UTR of NR4A2 mRNA. In renal cortex we found differential expression of 46 genes and 13 miRNAs. For selected genes we then confirmed expression differences for AIFM1, AMBP, APOE, CD36, EFNB1, NDUFAF1, PRDX5, REN, RENBP, SLC13A1, STX4, TNNT2 mRNAs, and for selected miRNAs hsa-miR-21, hsa-miR-126, hsa-miR-181a, hsa-miR-196a, hsa-miR-451, hsa-miR-638 and hsamiR-663. Functional experiments in HEK293 cells demonstrated that hsa-miR-663 can bind to the REN and APOE 3 0 UTRs and can regulate REN and APOE mRNA levels, while hsa-miR-181a regulated REN mRNA and AIFM1 mRNA. Our data demonstrated for the first time that miRNAs can regulate renin expression. The observed downregulation of two miRNAs in hypertension could explain the elevation in intrarenal renin mRNA. This study provides the first evidence to implicate renin and CD36 in essential hypertension etiology. It also reveals other mRNAs, as well as miRNAs and associated pathways, that are involved. As such it provides unique insights into essential hypertension etiology. This work has been accepted for publication in Hypertension.
4A.4. Novel insights into
4B.1. Improvement in cardiovascular risk factors in patients with diabetes by a community pharmacy education and monitoring project Background: PET-CT using 11 C-metomidate-a highaffinity ligand for the steroidogenic enzymes CYP11B1 and CYP11B2-is a non-invasive alternative to adrenal vein sampling (AVS) in patients with primary aldosteronism (PA). Our previous study reported 73% sensitivity and 87% specificity compared to AVS.
1 We now report use of PET-CT in patients referred with unsuccessful or equivocal AVS. Design: 17 patients with PA, and definite or equivocal adenoma on adrenal CT/MRI, underwent PET-CT. 200-500 mBq 11 C-metomidate was injected after 3 days dosing with dexamethasone 0.5 mg qds. At 35-45 min post-injection, standardised uptake values (SUV) were measured over tumour (T) and normal adrenal (N). Results: In all 17 patients, a confident diagnosis of unilateral (n ¼ 10) or bilateral PA (n ¼ 7) was made, using our SUV T:N ratio of 1.25:1.
1 Eight unilateral patients proceeded to adrenalectomy, which reversed aldosterone-to-renin ratio in all cases. The value of PET-CT is illustrated in the Figure, showing diagnosis of a sub-cm APA in the proband (left panel), leading to a similar result in the brother (right panel) and discovery of a new germline syndrome. Exome sequencing has been undertaken.
Conclusions:
11 C-metomidate PET-CT detects small APAs. This may be particularly important for nonclassical APAs which arise in zona glomerulosa and elude detection or surgery before development of resistant hypertension. Introduction: Capillary rarefaction is pathognomonic of essential hypertension (EH). We have previously shown that much of the capillary rarefaction in EH is due to the structural absence of capillaries. We have also shown significant capillary rarefaction in normotensive adult offspring of hypertensive parents, suggesting a familial predisposition in which capillary rarefaction represents a primary vascular abnormality that antedates the onset of sustained elevation of blood pressure. We hypothesized that infants born to mothers with hypertensive disorders of pregnancy would have significant capillary rarefaction at birth. Methods: We studied 22 such infants (gestational age 37.1 ± 3.3 weeks, birth weight 2585 ± 916 grams) and compared them to 40 normal birth weight infants born at term to normotensive mothers (gestational age 39.7 ± 1.1 weeks, birth weight 3337 ± 525 grams). We used orthogonal polarised spectroscopy to measure basal (i.e. functional) and maximal (i.e. structural) skin capillary densities according to a well-validated protocol.
5A.2. Rapid intervention with glyceryl trinitrate (GTN) in
Results: We found that term infants born to hypertensive mothers had significantly lower maximal capillary density (mean difference of À5.0 capillaries/mm 2 ; 95%CI À9.4 to À0.6, P ¼ 0.025). Conversely, preterm infants with low birth weight (LBW) born to hypertensive mothers tended to have higher basal and maximal skin capillary densities compared to term infants. Conclusions: While these results add further support to our belief that capillary rarefaction in essential hypertension is likely to be a primary vascular abnormality; the results in preterm infants may suggest that intrauterine environment may exert some influences on the remodeling of the microcirculation which may delay the onset of capillary rarefaction in these infants.
5A.5. Combined resistance/endurance training is more effective than endurance training alone in improving blood pressure and glucose metabolism in male hypertensive patients with coronary artery disease Caminiti G, Arisi A, Franchini A, Cioffi V, Cascelli G, Cerrito A, Volterrani M and Rosano G
S. Raffaele IRCCS, Rome, Italy
Purpose: To asses if a combined training including resistance training (RT) and endurance training (ET) is more effective than ET alone in improving blood pressure and glucose metabolism in hypertensive patients with coronary artery disease (CAD). Methods: Thirty-five male patients with stable CAD, median age 74±4 years, were enrolled. Twenty pts were randomized to group A performing the combined training and 15 patients to group B (ET only). At baseline and after 24 weeks all patients underwent a cardiopulmonary test, fasting insulin and glycemia assessment with HOMA-index calculation and 24-hour ambulatory BP monitoring. RT was performed at 50-60% of pre-training maximal strength. ET consisted on cycling or walking at 60% of VO2. Both RT and ET were performed 3 times/week.
Results:
No patients had adverse events during the follow up period. No patients withdrawn during the study period. After 24 weeks exercise time improved in both groups with significant intergroups differences. After 12 weeks A group had a greater reduction of daytime (À16% vs À7%; p 0.02) and night time (À19% vs À8; p 0.006) diastolic blood pressure, and lower daytime (À12% vs À9; p 0.07) and night time (À13% vs À6; p 0.002) heart rate than B group. Heart rate recovery at I min and HOMA index had a greater significant decrease in the A group (À18 ± 5; 1.1 ± 0.4 respectively) compared to B (À11 ± 5; 0.61 ± 0.2 respectively). Conclusions: The combined training seems to determine greater effects on diastolic BP, exercise tolerance and insulin resistance compared to ET alone in hypertensive patients with CAD. RH prevalence using RH-JNC is estimated at 9% in US populations. RH prevalence in a UK communitybased sample, using more stringent RH-NICE, is unknown.
5A.6. Prevalence of resistant hypertension in
Methods: Using an expert system that utilises primary care data to make patient-specific recommendations regarding CKD management (SEiKsystem for early identification of kidney disease) we extracted data from all patients present on SEIK between April 2010 and April 2011 with X1 BP reading. Demographic, co-morbidity, BP, laboratory and prescription data were obtained. Results: 50 970 hypertensive patients were analysed. RH prevalence (RH-NICE) was 0.9% [95% CI 0.8-1.0], with a further 7% .2] using RH-JNC definition. In addition, 49.3% had uncontrolled (UC) BP (4140/90 and on o3 antihypertensives and/or no diuretic). Use of submaximal ACEi/ARB þ CCB þ TD combination was more prevalent in RH-JNC vs. controlled BP (C) (28.2% vs. 18.9%, Po0.0001). Diuretic usage in C vs. UC was 36.8% vs. 18.4% (Po0.0001). Tablet compliance appeared not to differ between C, UC and RH. Conclusion: RH prevalence in a large UK communitybased sample using current UK definitions is considerably less than previous estimates. Extrapolation to the entire UK population over 16 years old (ONS 2010 population data) suggests B137 000 will have RH, based on BP measurements in Primary Care.
Poster abstracts
PA.1. Renal denervation in resistant hypertension-a prospective case series Background: Renal denervation (RD) by radiofrequency ablation (Symplicity, Medtronic s ) has been shown to reduce office blood pressure (OBP) by 32/ 12 mm Hg at 6 months in patients with resistant hypertension (RH). Unpublished data from several centres indicate lesser BP lowering than in the published trials and here we report the experience from our own tertiary referral centre. Method: Patients with OBP 4160 mm Hg and no secondary causes of hypertension and confirmed compliance with antihypertensive drugs were eligible for RD. Results: 13 patients (6 men) mean age 59.5±3.9 years with mean baseline OBP 183/103 mm Hg underwent RD. On average, patients took 4.4 anti-hypertensives and had median 5 (range 3-7) ablations per renal artery. At 6 months, mean OBP fell by 11/11 mm Hg ( ± 10/4), with 5/10 patients achieving X10 mm Hg SBP reduction. Daytime mean ABPM reduction was 7/3 ± 6/4 mm Hg. The following were associated with response to RD: number of radiofrequency ablations (with office SBP; P ¼ 0.03) and ABPM mean daytime pulse pressure (with ABPM SBP and DBP; P ¼ 0.03 and 0.004) and baseline eGFR (with office DBP; P ¼ 0.026). Early safety data demonstrates no procedure-related complications and no significant decline in renal function after one year. Conclusion: In our cohort we report markedly heterogeneous efficacy of renal denervation. Baseline pulse pressure and the number of RD ablations may be predictors of response to RD and warrant further exploration.
PA.3. Management of arterial hypertension in kidney transplanted and non-transplanted pateints with advanced chronic kidney disease Kaysi S, Hadj-Abdelkader M, Aniort J, Heng A and Deteix P University Hospital of Gabriel Montpied, Clermont-Ferrand, France
Arterial hypertension (HT) and its complications in kidney transplanted (T) and non-transplanted (NT) patients with Chronic Kidney Disease (CKD) are similar. The aim of this retrospective study was to find out whether the management of (HT) in these two groups was the same or not.
Patients and methods:
Files of patients who were seen in consultations in our department in 2010 were screened. We compared the management of (HT) in: 58 (T) patients in stage 4 and 5 of (CKD) and 85 (NT) patients in the same stage of (CKD). In the (T), there were 23 women and 35 men, mean age was 57 years, and there were 21 diabetics, while in the (NT) there were 40 women and 45 men, mean age was 67 years and there were 23 diabetics. Results: Mean arterial blood pressure was 136/75 in (T) and 140/79 in (NT), but 52% of (T) were in target ranges versus 41% in (NT).
In (T), 17% had mono-therapy, 31% had bi-therapy, 26% had tri-therapy and 21% had more than 3 drugs, in (NT) 22% had mono-therapy, 20% had bi-therapy, 22% had tri-therapy and 28% had more than 3 drugs. BMI were similar. Haemoglobin, Parathormone, and Lipid profiles were better controlled in (NT), Erythropoietin (EPO) usages was more frequent in (T). ACEs, ARBIs, calcium channel blockers, and diuretics were more used in (NT), while Beta blockers were more used in (T). Conclusion: Better management of arterial hypertension was noticed in kidney transplanted patients with advanced (CKD). Background: Blood pressure measurement is frequently performed in hospitals and primary care. A variety of blood pressure measurement methods exist and the aim of this study was to compare several methods of non-invasive blood pressure measurement with auscultation, the current goldstandard. Methods: In 68 subjects, systolic blood pressure (SBP) was measured simultaneously by Korotkoff sound auscultation over the brachial artery, oscillometry, and the cuff pressure at the return of arterial blood flow assessed by return of a Doppler radial arterial signal. The cuff pressure of the first digitally detected arterial sound was also determined by using a microphone in a second head of the stethoscope. Three recordings were made on the right arm with the forearm supported at heart height. The difference between the mean auscultatory SBP value and the mean values obtained by other modalities was calculated for each patient. Results: With respect to the auscultatory SBP value, the arterial flow returned 1.82 mm Hg (95% CI 0.59-3.04) higher, the first recorded arterial sound 4.71 mm Hg (95% CI 3.89-5.52) higher, and the average oscillometric value was 6.12 mm Hg (95% CI 4.73-7.52) higher; these values were all significantly different from auscultation (P ¼ 0.0043, Po0.0001, Po0.0001 respectively). SBP values determined by the first recorded arterial sound and oscillometry were also significantly higher than values determined by the return of arterial flow (Po0.0001, Po0.0001 respectively). Conclusion: Standard auscultatory SBP measurement results in lower SBP values than oscillometry and Doppler return-to-flow. Furthermore, digital arterial sounds can be detected before the first Korotkoff sound is heard. Central systolic blood pressure (cSBP) may be more predictive of cardiovascular events than brachial BP. Therefore, non-invasive methods of determining central BP, which are suitable for routine clinical use, are required. The aim of this study was to compare estimates of cSBP provided by the Centron cBP301 with those obtained with the widely used SphygmoCor system. In 60 subjects (30 females), age range 22-90 years, brachial BP was measured using the Centron device and then cSBP estimated using the Centron, and then SphygmoCor. In a subset of 16 subjects (8 females), measurements were repeated at rest and following the administration of glyceryl trinitrate (GTN). There was a strong correlation (r ¼ 0.98; Po0.001) between the estimates of cSBP obtained with each device (Figure 1 ). There was also good agreement between devices, with a mean difference ( ± SD) of 0.2 ± 3.5 mm Hg (P ¼ 0.5). Similarly, the devices were highly correlated and in good agreement following the administration of GTN, with the mean difference in cSBP ranging from 0.5±3.9 mm Hg to 2.3±3.7 mm Hg, across the measurement period. The Centron cBP301 and SphygmoCor devices produce similar estimates of cSBP, both at rest and in response to a pharmacological challenge. The Centron device is potentially suitable for routine clinical monitoring of central BP.
PB

PB.2. Non-invasive estimates
PB.4. 24 h ambulatory central BP measurement reveals significant variation in pulse pressure amplification between day and night Background: Arterial sound auscultation during sphygmomanometer cuff deflation is considered gold-standard for non-invasive blood pressure measurement. However, little is known about how these sounds vary between subjects and in different positions. The aim of this study was to determine the average arterial sound acoustic frequency and assess variation with subject position, body mass index (BMI), age and arm circumference. Methods: In 33 subjects with a normal BMI and 31 obese subjects, arterial sounds were recorded using a microphone in a stethoscope limb. Six recordings were made on the right arm (forearm at heart height)-three while seated (standard position) and three while standing. Six recordings were also made on the fully-extended left arm; three with the arm angled 301 upward and three 301 downward.
Results: The mean average arterial sound frequency was 42.6 Hz (95% CI 40.6-44.7). With the arm angled downwards, the average frequency was 44.1 Hz (95% CI 39.5-48.8), compared to 35.7 Hz (95% CI 32.4-38.9) when angled upwards (P ¼ 0.0033). There was no change between sitting and standing (P ¼ 0.4177). In the standard position, the average frequency in the normal BMI group was 55.6 Hz (95% CI 47.9-65.4) compared to 35.7 Hz (95% CI 30.6-40.9) in the obese group (P ¼ o0.0001). In regression analysis, average frequency decreased with BMI (b ¼ À0.451; P ¼ 0.02) but not with age (P ¼ 0.345) or arm circumference (P ¼ 0.857). Conclusion: Given the acoustic sensitivity of the human ear decreases at low frequencies, the Korotkoff sounds are likely to be harder to detect with increasing BMI and arm elevation.
PB.6. A study into reproducibility of peripheral artery tonometry
Carty DM 1 , Degnan AJ 1 , Shah N 1 , Schneider MP 1,2 , Petrie JR 1 and Delles C 1 1 University of Glasgow, Glasgow, United Kingdom and 2 University of Erlangen-Nürnberg, Nürnberg, Germany
Background: Peripheral artery tonometry (PAT) is now used in multi-centre clinical trials to assess endothelial function. The standardised setup promises user-independent acquisition of data. We studied the reproducibility of this method in healthy volunteers. Methods: Nineteen healthy volunteers (14 female: age, 24±5; 5 male: age, 21±1 years) underwent assessment of endothelial function using the Endo-PAT2000 device on three occasions with at least one week intervals between study visits. We report here automated read-outs of Reactive Hyperaemia Index (RHI; a measure of flow-mediated vasodilatation, and Augmentation Index (AIx; a marker of wave reflection). Results: Mean RHI was 2.34 ± 0.58 in females and 1.92±0.28 in males (P ¼ 0.053), and AIx was À9±10 vs À15±4% (P ¼ 0.159). When only females were analysed, coefficients of variation (CVs) of systolic (SBP) and diastolic blood pressure (DBP) and RHI across all study visits were 9, 13 and 30%, respectively. Two investigators performed a similar number of study visits in female volunteers and produced similar grouped data (RHI, 2.38 ± 0.80 vs 2.34±0.63; AIx, À8±13 vs À10±7%). CVs of RHI in males (25%) and females (30%) were similar. When the three study visits were compared, RHI was similar across study visits (2.16 ± 0.62, 2.28 ± 0.66 and 2.28±0.78). For the three study visits, intraindividual CVs for RHI ranged between 9 and 40% (median, 18%). Conclusions: Two investigators obtained very similar data on endothelial function, suggesting low operator dependency. As with other measures of endothelial function, we found a relatively high between day intra-subject variability of RHI.
PB.7. The first Korotkoff sound (K1) originates more proximally than the point of auscultation Systolic blood pressure (SBP) within the arm decreases with increasing arm elevation and vice versa, probably due to the gravitational effect on the column of blood within the arm. We utilise this relationship to determine a possible site of origin of K1. In 65 patients, SBP was simultaneously measured by sphygmomanometer cuff pressure at the return of Doppler arterial blood flow (SBP-RDF) during cuff deflation and by auscultation (SBP-K1) with the fully-extended arm angled 301 upwards, horizontal at shoulder level, and 301 downwards. Three measurements were made in each position in randomised order. There was no mean difference between SBP-RDF and SBP-K1 in the horizontal position (0.00 mm Hg; 95% CI À1.69-1.69; P ¼ 1.000) but significant differences with the arm angled upwards and downwards (P ¼ 0.0023, P ¼ 0.0005 respectively). With the arm angled upwards, SBP-RDF decreased by 11.05 mm Hg (95% CI 8.55-13.55) and SBP-K1 decreased by 8.15 mm Hg (95% CI 6.46-9.84) relative to the horizontal arm position. With the arm angled downwards, SBP-RDF increased by 7.82 mm Hg (95% CI 5.83-9.80) and SBP-K1 increased by 5.89 mm Hg (95% CI 4.11-7.67) relative to the horizontal arm position. The gravitational effect on the blood column within the arm is less pronounced with auscultatory SBP measurement. This suggests the first Korotkoff sound originates at a more proximal arterial site than downstream of the cuff where the sounds are heard.
PB.8. Can we improve hypertension management in primary care using protocols developed in secondary care nurse-led hypertension clinic?
Denver E and Barnard M Whittington Health Trust, London, United Kingdom Aim: To improve the local management of blood pressure (BP) by setting up Practice Nurse-led Hypertension Clinics in primary care, using protocols developed in the hospital diabetes clinic. Background: People who have diabetes are at increased risk of coronary heart disease and cerebrovascular disease. Effective BP treatment is hard to achieve. Often action is not taken on increased BP and tight targets are not always appreciated. Method: The project ran from 2006 till 2010, with 2 courses. General Practitioners (GPs) and Practice Nurses (PNs) from the local Primary Care areas were invited to a north London Hospital to attend teaching sessions covering various topics in hypertension management. The sessions were interactive and focused on implementing hypertension care pathways within the Practice and taking action on raised BP, and included how to use and implement the pharmacological pathways developed in the Hospital Nurse-led Hypertension Clinic. Each practice was offered assistance in setting-up a Practice Nurse-led Hypertension Clinic (NLC) and over the following 6 months the providers acted as mentors to the PNs and GPs. All participants were invited at the end of 12 months to a meeting to discuss local problems they had experienced in setting up an NLC and to talk about interesting cases. Attendance at this was poor. Only one Practice had set up an NLC, the most common reason being lack of time. However, feedback from the courses was very positive, and all said they had learned a lot and changed their practice.
PB.9. Confirmation of drug adherence before renal symapathetic denervation-the role of drug efficacy clinic Appunu K, Tesbitt L, Jacques N, Hadley G, Thomas M and Dasgupta I Heart of England NHS Trust, Birmingham, United Kingdom Resistant hypertension is common. A significant proportion of this is considered to be due to nonadherence to prescribed medication. It is important to rule out non-adherence before renal denervation is performed. Here we report our experience from Drug Efficacy Clinic (DEC) designed to assess adherence. Eighteen patients with resistant hypertension as defined by the BHS guidelines were included. The mean [SD] The prevalence of cardiovascular risk factors is higher in South Asian (SA) adults compared to White Europeans (WE), although the reasons remain unclear. As vascular growth factors (VGF) are thought to contribute to vessel development, function and remodeling, we undertook a pilot study to investigate whether ethnic differences exist in VGF levels in early life. Serum samples were obtained from children (WE 95, SA 45, other 12) at various ages between 3 and 48 months, with repeated sampling in some children. Samples (n ¼ 80 to 151) were assayed for platelet derived GF, osteoprotogerin, fibroblast GF, vascular endothelial GF, epidermal GF, hepatocyte GF and placental GF. Aortic pulse wave velocity (aPWV) was measured in 63 children. Across both main and the other ethnic groups, significant differences were seen in EGF (Kruskal Background: The Hypertrophic Heart Rat (HHR) is a normotensive model of human polygenic cardiac hypertrophy, which has a reduced complement of cardiomyocytes from birth, leading to hypertrophy, cardiac failure and premature death in adulthood. We aimed to investigate the regulatory mechanisms at the genome-level that govern these processes. Design and methods: Genome-wide transcriptome expression was measured by Affymetrix Rat Gene ST Arrays using RNA from the left ventricle of neonatal HHR and control rat, the Normal Heart Rat (NHR) (n ¼ 16). Results: Statistical analysis identified 109 differentially expressed genes in cardiac ventricle of male HHR (FDR Po0.05 and fold change 41.5). 55% of those were in quantitative trait loci for cardiac mass. The gene for lipocalin-2 (Lcn2) showed 12-time higher fold change in the HHR, and was further validated by real-time PCR (P ¼ 0.0001). Lcn2 has been recently described as a critical regulator of cell proliferation, autophagy and mitochondrial function. Gene ontology analysis highlighted an overrepresentation of genes related to autophagy, cell differentiation and DNA replication. Other genes in autophagic pathways, such as RT1-DMb (P ¼ 0.0005; fold change ¼ 2.6) and Chid1 (P ¼ 0.0008;fold change ¼ 2.4), were validated. This is consistent with our previous results of increased autophagy in response to stressors and increased proportion of binucleated cardiomyocytes observed in neonatal HHR. Conclusions: These findings suggest that dysregulation of genes involved in autophagic pathways during the neonatal period may be an important regulatory mechanism governing cardiomyocyte differentiation in the HHR. Further studies to characterise the role of Lcn2 in autophagy and cardiac hypertrophy are underway.
PD.4. M1-D1, a potential novel measure of arterial stiffness independent of blood pressure: a preliminary study Mansbridge Arterial stiffness is a recognised measure of vascular health. We suggest a novel measure of arterial stiffness. During sphygmomanometer cuff deflation in a standard arm position, the cuff pressure at the first arterial sound (M1) and the return of arterial blood flow (D1) is noted. The difference in cuff pressure between these two entities (M1-D1) is calculated. We tested this measure in 34 subjects with a normal body mass index (BMI) and 31 obese subjects. An automated blood pressure device was employed to provide a constant rate of inflation and deflation of the cuff; a microphone inside one head of a stethoscope recorded arterial sounds; and a radial Doppler ultrasound recorded blood flow. All data was channelled into a computer for analysis, and M1-D1 was assessed using the cuff pressure at the first digitally detected arterial sound and the cuff pressure at the return of blood flow. Three measurements were made on each subject at one minute intervals. M1-D1 had inter-quartile range of 0.00 to 5.00 mm Hg. M1-D1 was 4.47 mm Hg (95% CI 2.55 to 6.39) in normal BMI subjects compared to 1.16 mm Hg (95% CI 0.06 to 2.26) in obese subjects (P ¼ 0.0042). In linear regression analysis, M1-D1 decreased with age (b ¼ À0.270; P ¼ 0.039) but not SBP (P ¼ 0.287) or arm circumference (P ¼ 0.748). There was a significant correlation between pulse pressure, determined by the automated device, and M1-D1 (r ¼ À0.352, P ¼ 0.004). Decreased M1-D1 values are likely to be associated with increased arterial stiffness. M1-D1 deserves further investigation as measure of arterial stiffness. Endothelin (ET) receptor antagonists, bosentan and ambrisentan, are licensed for treatment of pulmonary arterial hypertension (PAH). The ET peptides act via two G-protein-coupled receptors (GPCRs), ET A and ET B . However, GPCRs may also activate signalling pathways in a G-protein-independent manner via b-arrestin. Evidence is emerging that ligandspecific pathway modulation (biased agonism/ antagonism) may have therapeutic application and therefore we have investigated the potential for pathway bias of ET agonists and antagonists. Concentration-response curves were constructed to ET agonists using ET A and ET B b-arrestin assays. ET receptor antagonists were tested for their ability to block ET-1 responses in each assay and agonistdependence of the ET A selective antagonist BQ123 was also investigated. These data were compared to results from binding experiments in human heart (that expresses both subtypes) and to ET A -mediated vasoconstrictor experiments in human saphenous vein. The relative potency of ET peptides in the b-arrestin assays were ET-1XET-2cET-3 for ET A and ET-1 ¼ ET-34ET-2 for ET B . Interestingly, for ET A , compared to ET-1, all agonists tested were partial agonists. Differences from the known pharmacology of antagonists were also revealed in the b-arrestin assays. Specifically, BQ123 behaved as a negative allosteric modulator in the ET A assay, exhibiting agonist-dependent affinities. Bosentan was a potent ET A -selective antagonist in the b-arrestin assay in contrast to its non-selective profile determined in human heart. The apparent ET A b-arrestin bias of bosentan may contribute to its clinical effectiveness in PAH but further investigation of a role for functional selectivity and biased signalling via the ET receptors in cardiovascular disease is required. Severe acute malnutrition (SAM) can have either an oedematous or non-oedematous phenotype and their metabolic effects may persist into adulthood. We hypothesised that cardiovascular structure and function would differ between phenotypes as young adults and between survivors and persons never exposed to SAM. Methods: We recruited 54 non-oedematous and 62 oedematous adult survivors of SAM, and 45 age/sex/ BMI-matched community controls. Standardised measures of anthropometry, blood pressure (BP), 2D-echocardiography, carotid and femoral artery ultrasound, brachial, radial and carotid tonometry were performed. Cardiac output (CO), stroke volume (SV), left ventricular mass (LVM) index and outflow tract (LVOT) diameter, carotid and femoral intimamedia thickness (IMT), carotid-femoral pulse wave velocity (PWV) and augmentation index were derived. Visceral fat mass was assessed by CT scan.
PD.5. Pharmacology of human ET
Results: Mean (SD) age was 28.8 (7.8) years; 55% were male. Visceral fat mass and BP did not differ significantly between groups. There were no significant differences in cardiovascular measures between oedematous and non-oedematous survivors. After adjusting for age, sex, height and weight, measurements in controls exceeded survivors' expressed in mean (SE) standardized units, as follows: LVOT diameter 0.68 (0.16, Po0.001), CO 0.53 (0.16, P ¼ 0.001), SV 0.44 (0.17, P ¼ 0.009), femoral IMT 0.71 (0.19, Po0.001) and PWV 0.32 (0.15, P ¼ 0.03). Conclusions: Adult survivors of SAM had less arterial stiffness and decreased CO (due mainly to a smaller SV) compared to controls. The nutritional insult in early childhood may have effects on organ growth and therefore cardiac function. However, at this young age, there was no impact on vascular structure and function.
PE.4. Renal sympathetic denervation for resistant hypertension in a patient with severe CKD: a first report Dasgupta I, Watkin R, Freedman J and Crowe P Heartlands Hospital, Birmingham, United Kingdom
Resistant hypertension is common in severe CKD. Renal denervation (RSD) is effective in controlling BP in resistant hypertension (Simplicity -HTN 1 & 2) . These studies excluded patients with eGFR o45 ml/ min/m 2 . We report the first case, to our knowledge, of RSD done in a patient with severe CKD in the UK. RSD was established in our centre in October 2011. True resistance is established by means of ABPM, excluding secondary hypertension and adherence confirmation by supervised treatment. A 31 year old lady was referred with eGFR 30 and resistant hypertension. Renal biopsy showed crescentic IgA nephropathy. Despite stepwise increase in medication BP control remained poor. Clinic BP before RSD was 186/124 mm Hg and eGFR 19. She was on lisinopril, amlodipine, doxazocin, moxonidine, bisoprolol, and furosemide daily at maximum tolerated doses. The mean daytime ABPM was 168/103. MRA of renal arteries, urine metanephrines and cortisol, and serum aldosterone:renin were normal. Adherence was confirmed. The procedure went uneventfully; there was no immediate drop in BP. At 1 month, clinic BP was 168/105 and eGFR 19. At 3 months clinic BP was 178/98 and eGFR 20. At 6 months BP was 180/124 and eGFR 17. Urine protein creatinine ratio remained unchanged. Mean daytime ABPM at 3 months was 166/104. The procedure was safe with no drop in eGFR but failed to control BP in 6 months. Is RSD effective in patients with severe CKD? A cohort study of RSD in severe CKD is needed to assess safety and efficacy of the procedure. and 53 patients beta blocker alone. In ACE-I group age at enrolment was 62 ± 13 years, 57.7% were females, at baseline duration of diabetes was 14.2 ± 7 years, eGFR 96±38 ml/min, serum creatinine 79± 58 mmol/l, body mass index 30.5 ± 4.9 kg/m 2 , systolic blood pressure 136 ± 18, diastolic blood pressure 78.7±10.4 mm Hg, baseline characteristics were insignificantly different in patients receiving ACE-I, calcium channel blocker or beta blocker. Amongst patients, taking ACE inhibitors for five consecutive years there was higher incidence of proteinurea, doubling of serum creatinine, and greater number of patients with eGFRo60 ml/min. There was a significantly (Po0.05) greater decline in GFR, and ESRD requiring dialysis without increase in the mortality. Conclusion: Deterioration of kidney function was noted in diabetic patients receiving ACE-I. on long term basis kidney function monitoring is desired with the long term use of ACE-I.
